SCYX-7158

Phase 1Small molecule

DDrugs for Neglected Diseases

SCYX-7158 is one of 5 small molecule programs targeting Human African Trypanosomiasis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Human African TrypanosomiasisActive, not recruiting

Human African TrypanosomiasisPhase 1

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Human African Trypanosomiasis

#DrugCompanyPhaseTrials

Lampit

Bayer

Phase 3

2 2

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Phase 3

2 3

Fexinidazole

Sanofi

Phase 3

6 4

Acoziborole

DDrugs for Neglected Diseases

Phase 3

1 5

SCYX-7158

DDrugs for Neglected Diseases

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Human African Trypanosomiasis1 trial

Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158

Completed·DDrugs for Neglected Diseases·Phase 1·NCT01533961·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SCYX-7158. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCYX-7158 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCYX-7158. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Drugs for Neglected Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDrugs for Neglected Diseases

SCYX-7158

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Human African Trypanosomiasis1 trial

References

Drug Info

Quick Facts

Related News